Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
about
Thromboprophylaxis for trauma patientsUnfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patientsThromboprophylaxis for trauma patientsAnticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current IssuesClinical Scenarios for Discordant Anti-XaCan heparins stimulate bone cancer stem cells and interfere with tumorigenesis?A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyReview article: Venous thromboembolism after total joint replacementModels for thrombin generation and risk of diseaseHigh-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitorsEnoxaparin in acute coronary syndromesAnticoagulants and the propagation phase of thrombin generationVenous thromboembolism: classification, risk factors, diagnosis, and management.In vitro and in vivo characterization of a reversible synthetic heparin analog.A data-driven approach to optimized medication dosing: a focus on heparinDiscovery of heparin chemosensors through diversity oriented fluorescence library approach.Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinSuccessful percutaneous coronary intervention using bivalirudin in a patient with chronic lymphocytic leukemia and thrombocytopenia.Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options.Beyond heparin and warfarin: the new generation of anticoagulants.Latest medical treatment strategies for venous thromboembolism.Clinical review: Patency of the circuit in continuous renal replacement therapyDeterminants of PF4/heparin immunogenicityCurrent concepts review: heparin-induced thrombocytopenia.Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.Reversible crystallization of argatroban after subcutaneous application in pigs.Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.Platelet Consumption and Filter Clotting Using Two Different Membrane Sizes during Continuous Venovenous Haemodiafiltration in the Intensive Care Unit.The Successful Use of Enoxaparin in the Lack of Bivalirudin in a Patient with Chronic Lymphocytic Leukemia and Thrombocytopenia who Underwent Percutaneous Coronary Revascularization.Trends in the development of oral anticoagulants.The Treatment of Venous Thromboembolism in Patients with Cancer.Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.Polyphosphate as a general procoagulant agent.Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial.Photochemical Preparation of a Novel Low Molecular Weight HeparinAnticoagulation by factor Xa inhibitors.Deep vein thrombosis: a clinical review.Defining the boundaries of normal thrombin generation: investigations into hemostasisUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.
P2860
Q24198771-419FE1B5-C5C9-4A36-A7CD-4DD9EF524AA1Q24200589-B3DEB476-42BA-4960-8E7C-9CEE9DD07861Q24241192-2D0261E1-A772-4D5A-B438-D00B09B410DAQ26742088-5F217D3B-861A-4A6A-AD8B-16D77F886628Q26746987-155FCE55-C467-4FD0-99EE-BAA1FB365554Q26852760-0BF07971-7A9D-477A-8B2E-D0A30FC9C659Q26995027-B40AFC3E-4DD2-4286-BE80-339192687A23Q27006824-FA7BA201-BB4B-489B-8AA7-8744DA04767EQ27013171-3B56B9AB-CFEA-48BC-B766-C1B7246A890EQ27678539-CC0058A5-3C47-4426-A456-34CDE938186EQ28301431-D6139C8B-E9C6-42DA-ADB8-9597738CE661Q28742536-1A82AF1A-D270-4337-8CEB-D30F71127478Q30472938-A6A7D196-F283-414E-9E9A-1E4957B21207Q30710756-9ACC8AEE-AACC-43A0-8477-B18BDAD4E668Q30840644-5C163F1B-FFEC-427B-8FDB-1E603A3ED955Q33321780-D80D80FD-686B-48EA-80EE-DB2AD0F5CF86Q33365781-EF644343-DA54-4990-AFF2-2318DAE36BB8Q33367978-EC977277-1034-4169-A889-E5403D15F482Q33372584-6E20636C-D921-421E-AD9F-4E745DD2B55FQ33373128-F8501DE3-1512-48F9-A21B-E732CCB30CBCQ33374258-0279E54A-01F2-4940-9F87-E7816196E169Q33375535-9C73687D-10DA-4174-9A25-CA4694D18BC7Q33375906-72CC9423-EB7D-480A-8C49-8DACF0041022Q33376629-7BC872AC-3ED1-4D60-B7BD-CAE74869EE3EQ33382108-BCDB5A47-9710-41D5-A0E2-2298F3B5DDBCQ33399005-4934FA19-1A7D-4AE9-9D98-DCB3F691DB75Q33403381-0F696197-2D0B-4280-8FD2-505727E5BC1AQ33406904-62DDFB3B-2CBB-436D-8B25-3A9C3B264A12Q33415569-1D60178D-EC73-4207-BFB8-D4CB420B7A81Q33419923-62EDAF1E-5170-42F6-8A39-E6D1CFCBD001Q33424198-EAA6C77E-89FA-4B63-9C85-B0F95779745CQ33435329-C872E30D-F4D8-4794-A9E0-DA998ED38E1FQ33441234-E0D65181-186D-44A6-87B5-B31BA8C5D417Q33724794-B86C24EA-6C54-46B1-B327-4A9A7D337D76Q33919099-B7A85B1A-7E5C-4193-8356-09B446F45D8CQ34113419-39D95432-DE95-43FE-8313-8934ED295ED0Q34130097-DF289D0B-66BC-491A-B3A3-A26228881AEAQ34144439-713F9DA2-229E-4B65-8C05-998837519A29Q34154574-C74E9F9E-0EA7-4791-A745-222CA68CA614Q34352446-D2F78D11-30C4-4D36-822C-6F2949861152
P2860
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@ast
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@en
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@nl
type
label
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@ast
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@en
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@nl
prefLabel
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@ast
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@en
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@nl
P1433
P1476
Heparin and low-molecular-weig ...... otic and Thrombolytic Therapy.
@en
P2093
Jack Hirsh
Robert Raschke
P304
P356
10.1378/CHEST.126.3_SUPPL.188S
P407
P433
P577
2004-09-01T00:00:00Z